Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study

International Journal of Clinical Practice

Volumn 64, Issue 8, 2010, Pages 1042-1051

  Montorsi, F ^a   Henkel, T ^b   Geboers, A ^c   Mirone, V ^d   Arrosagaray, P ^e   Morrill, B ^f   Black, L ^f  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b Consultant Urologist ^*  (Germany)

^c SLINGELAND HOSPITAL   (Netherlands)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e HOSPITAL DE MENDARO   (Spain)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BPH IMPACT INDEX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT PERCEPTION OF STUDY MEDICATION; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE FLOW RATE; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; AZASTEROIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77953861450     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02428.x     Document Type: Article

References (19)

1. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Eur Urol 1997 31 : 272 280.
2. Robertson C, Link CL, Onel E et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int 2007 99 : 347 354.
3. Fourcade RO, Théret N, Taïeb C. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European Countries. BJU Int 2008 101 : 1111 1118.
4. Barkin J, Roehrborn CG, Siami P et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 2009 103 : 919 926.
5. Roehrborn CG, McConnell JD, Barry MJ et al. AUA guideline on the management of benign prostatic hyperplasia (BPH) 2003. Updated 2006. Available at: http://www.auanet.org/content/guidelines-and-quality-care/clinical- guidelines.cfm?sub=bph [accessed 5th February 2010].
6. de la Rosette JJ, Alivizatos G, Madersbacher S et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001 40 : 256 263.
7. Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004 172 : 2321 2325.
8. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004 46 : 547 554.
9. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU Int 2003 92 : 262 266.
10. Bruskewitz R, Girman CJ, Fowler J et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Urology 1999 54 : 670 678.
11. McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol 2006 175 : 35 42.
12. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcomes, and factors predicting response. J Urol 1998 160 : 1358 1367.
13. Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trial 2007 28 : 770 779.
14. Roehrborn CG, Siami P, Barkin J et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008 179 : 616 621.
15. Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010 57 : 123 131.
16. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients. J Urol 1995 154 : 1770 1774.
17. Chatelain CH, Denis L, Foo JK et al. (2001) Recommendations of the International Scientific Committee: evaluation and treatment of lower urinary tract symptoms (LUTS) in older men. In : Chatelain C, Denis L, Foo KT, Khoury S, McConnell J, eds. Fifth International Consultation on Benign Prostatic Hyperplasia.
18. Black L, Grove A, Morrill B. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes 2009 7 : 55.
19. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 2398.